Humulin 70-30 Articles

Stock Commentary - New York

12 July 2004

Novo Nordisk to buy Indar?

12 July 2004

Expanded use for Novartis' Sandostatin LAR in UK

5 July 2004

Chromium picolinate supp may reduce some key symptoms of atypical depression

5 July 2004

Generex enters $25M Oralin deal

5 July 2004

Tercica pays Genentech $1.3 million under IGF-1 combined with IGFBP-3 deal

28 June 2004

Novo Nordisk's Levemir available in UK

28 June 2004

Avandia may reduce diabetes in ethnics

14 June 2004

Abbott introduces new, improved Xtra diabetes management system

14 June 2004

Lilly reviews investment in France

14 June 2004

EU clears Novo Nordisk's Levemir

14 June 2004

Positive Aventis' Exubera data at ADA

14 June 2004

Positive EU opinion for Aventis' Apidra

14 June 2004

Eiffel Tech completes Level One ADR program

7 June 2004

US Rx co-pay rises "cut drug use up to 23%"

31 May 2004

Pfizer's Somavert available in UK

31 May 2004

Rodman and Renshaw conference sees many drug modification-focused firms

31 May 2004

Wockhardt to export insulin to SE Asia

24 May 2004

Roche claims more than 12 products in pipeline with blockbuster potential

10 May 2004

Tercica gets rights to rhIGF-I from Fujisawa

10 May 2004

Biotech Holdings starts producing Sucanon

26 April 2004

FDA clears Aventis' insulin Apidra

26 April 2004

Hungarian govt goes ahead with 15% drug price reductions

19 April 2004

Novo Nordisk breaks ground on new facility

12 April 2004

$5M B-MS milestone for Flamel

5 April 2004

Generex enters JV in Cent and S America

5 April 2004

Biotech Holdings says Sucanon facility on schedule

29 March 2004

Glucophage to get expanded EU label

22 March 2004

Sanofi's Acomplia addresses multiple risk factors associated with CVD

22 March 2004

Serologicals expands distribution deal with Novo Nordisk

15 March 2004

Detailing rejection of Sanofi bid, Aventis says it is opportunistic, under-values firm

15 March 2004

Aventis/Pfizer's Exubera filing accepted by EMEA

15 March 2004

Biotech Holdings to start Sucanon production

8 March 2004

Novo Nordisk's Levemir on track in EU

8 March 2004

Aventis to see if Lantus reduces CVD risk

1 March 2004

Positive data for NOBEX' insulin product

1 March 2004

Aventis files insulin delivery device

23 February 2004

Novo Nordisk profits up 19% in 2003

16 February 2004

Aventis still argues against Sanofi bid

16 February 2004

Aventis highlights its late-stage pipeline to justify its stand-alone strategy

16 February 2004

Aventis reports robust results for 2003 and cements its stand-alone position

16 February 2004

Strong 2003 sales for Lilly but profits flat

9 February 2004

Novo Nordisk expands French insulin production capacity

2 February 2004

Andrx and Takeda in diabetes deal

19 January 2004

SomatoKine gets FDA Orphan Drug status

5 January 2004

Japan's Fujisawa sets out plans for continuous growth

8 December 2003

Aventis continues its transformation, comments broker

24 November 2003

Transition and Novo Nordisk sign deal

17 November 2003

BioSante's long-acting inj insulin trial positive

17 November 2003

Generex starts studies in diabetic teenagers

10 November 2003

Profits up at Aventis in 3rd quarter, but full-year sales forecasts lowered

10 November 2003

Serono beats expectations with 3rd-qtr 2003 net income up 48%

3 November 2003

Remicade, Avandia, Actos, EpiPen join Australia's PBS; Gleevec's listing widened

3 November 2003

Flamel gets US Ok for Basulin deal with B-MS

27 October 2003

Aventis' Lantus appro in Japan for diabetes

27 October 2003

Approvable letter for Levemir from FDA

20 October 2003

Russian/German insulin venture

20 October 2003

Aventis puts timetable on sales of stakes in Clariant and Rhodia

29 September 2003

German drug industry investment stays high despite reform

29 September 2003

FDA warns pharmacy supplying US city

29 September 2003

Aventis launches Lantus in India

22 September 2003

$100,000 SBIR grant for BioSante

22 September 2003

Novo Nordisk invests 130 million euros in insulin cartridge facility

22 September 2003

Tokyo pharma stocks - week to Sept 8

15 September 2003

B-MS and Flamel in Basulin licensing deal worthup to $165 million

8 September 2003

Novo Nordisk

8 September 2003

Russian health care spending for 2004

8 September 2003

Novo Nordisk

18 August 2003

Roche discovers new diabetes type 2 class

28 July 2003

Majors rush to roll out new drugs in Japan

14 July 2003

New US Rx plan offers cost-sharing options

14 July 2003

India: Phase III trials for biotech imports

14 July 2003

Stock Commentary - Europe

30 June 2003

Pfizer's Lipitor reduces heart attacks and strokes in diabetic patients

23 June 2003

GenMedix to set up $34M unit in Malaysia

23 June 2003

Canadian R&D and generics firms clash in parliament over patent regs and TRIPS

16 June 2003

Merck KGaA halts diabetes projects

9 June 2003

India acts on prices of 87 drug formulations

9 June 2003

Merck KGaA revamps R&D programs

9 June 2003

Lilly and Generex end diabetes deal

2 June 2003

Parallel imports

26 May 2003

Isis starts trials of diabetes compound

19 May 2003

The impact of generics in the USA: an overview from Merrill Lynch

19 May 2003

Taisho exits diabetes alliance with Neurocrine

12 May 2003

Novo Nordisk continues Clayton, USA, expansion

12 May 2003

Underlying growth beats forecasts at Lilly

28 April 2003

B-MS extends range of Glucophage XR

21 April 2003

rDNA biotech imports require trials, says India

14 April 2003

McClellan says FDA will encourage generics but slams makers over approval delays

14 April 2003

Pharmacia gets US approval for acromegaly treatment Somavert

7 April 2003

Roche starts tender offer for Disetronic

31 March 2003

Phase II results back exenatide role in diabetes

31 March 2003

Tokyo pharma stocks - week to Mar 24

31 March 2003

Aventis' Lantus gets pediatric OK in EU

24 March 2003

Dundee Univ $24.5 M deal with six drug majors

24 March 2003

NovoLog FlexPen launched in USA

10 March 2003

GSK's Avandia cleared for use with insulin

10 March 2003

UK NICE issues flu and diabetes guidances

3 March 2003

Ono halts diabetes drug trial

3 March 2003

Strong 4th-quarter operating results at Merck KGaA on flat sales

24 February 2003

Showing 601-700 of 1572 articles

Go to beginningPreviousNextGo to end